Biotech Firms' Financing and the Capitalism Model: A Historical Baseline (1997–2008) and an Updated Reading for the Post-Crisis Era

Le financement des entreprises biotechnologiques et le modèle de capitalisme: référence historique (1997-2008) et lecture actualisée pour l'ère post-crise

Lysiane Tendil ()
Additional contact information
Lysiane Tendil: Independent Researcher

Working Papers from HAL

Abstract: This paper investigates whether the structural features of national capitalism — captured by the dichotomy between market-oriented (MOM) and bank-oriented (BOM) models — shape the financing decisions of innovative firms. Using an international panel of 1,064 listed biotechnology firms from 16 developed economies over the 1997–2008 period, drawn from Datastream / Thomson Financial, I estimate the determinants of stock issues (SI/TA) and of financial leverage (TD/TA) and contrast them across capitalism models. Three results stand out. First, operating cash flow and R&D intensity are positive and highly significant determinants of stock issues in both market-oriented sub-samples, while the same cash-flow effect is far weaker in bank-oriented economies — a contrast consistent with deeper equity-market support for high-burn biotech R&D in MOM systems. Second, several other determinants — the non-debt tax shield, sales intensity, historical risk and the financing deficit — enter with signs and significance levels that differ across MOM and BOM economies, consistent with a persistent institutional segmentation. Third, the determinants of financial leverage are themselves institutionally patterned, with asset tangibility and firm size playing markedly stronger roles in bank-oriented economies. The empirical estimates are drawn from a fixed-effects panel specification, selected on Fisher, Breusch-Pagan and Hausman tests. The paper closes with an extended discussion of what has changed since 2008 — the post-crisis monetary regime, the 2013–2021 biotech IPO boom, SPACs and direct listings, the rise of Asian biotech, and AI-driven drug discovery — and argues that the convergence-versus-segmentation debate remains open. The 1997–2008 results are best read as a historical baseline against which post-crisis empirical work should now be calibrated.

Keywords: biotech firms capitalism models equity financing stock issues panel data institutional finance. JEL classification: G15; financement par actions; émissions d'actions; levier financier; market-oriented; bank-oriented; données de panel; finance institutionnelle; modèles de capitalisme; entreprises biotechnologiques (search for similar items in EconPapers)
Date: 2026-05-17
Note: View the original document on HAL open archive server: https://hal.science/hal-05624387v1
References: Add references at CitEc
Citations:

Downloads: (external link)
https://hal.science/hal-05624387v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:wpaper:hal-05624387

Access Statistics for this paper

More papers in Working Papers from HAL
Bibliographic data for series maintained by CCSD ().